Scientific Meeting: Neuroscience and Psychoanalysis: Two Sciences or One?
-
February 24, 2024
11:00 am - 1:00 pm
- Buy your ticket at nypsi.org. PLEASE NOTE: Ticket Registration is NOT the same as ZOOM registration.
- At least one day prior: Complete ZOOM registration for meeting which you will receive by email from Sharon Weller. This step involves entering your name and email address. If you do not complete this, you will NOT receive link to meeting. PLEASE CHECK ALL EMAIL FOLDERS IN CASE IT GOES INTO SPAM OR OTHER FOLDER. YOU MUST COMPLETE BOTH NYPSI WEBSITE REGISTRATION AND ZOOM REGISTRATION.
- After completing ZOOM registration, click on JOIN MEETING button in email from Emily Summers (host) in order to “enter” the meeting.
- Evaluation and CME/CE documentation will be emailed day after the event.
NYPSI’s 1072nd Scientific Meeting:
“Neuroscience and Psychoanalysis: Two Sciences or One? Mark Solms and Ariane Bazan in Debate”
Saturday, February 24, 2024
11:00 AM – 1:00 PM (EST)
Panelists: Ariane Bazan, Ph.D., Mark Solms, Ph.D. and Charles Fisher, M.D. (moderator)
“Neuroscience and Psychoanalysis: Two Sciences or One? Mark Solms and Ariane Bazan in Debate,” is a program intended for members of the psychoanalytic community at large. Two distinguished psychoanalysts and neuroscientists will present their views and engage in a moderated debate before opening the program to include the audience. Mark Solms, the founder of Neuropsychoanalysis, views neuroscience and psychoanalysis as a single science with dual aspects. Ariane Bazan sees a duality in which the body and the mind have fundamentally different laws and regulatory principles. Both agree that the dialogue between psychoanalysis and neuroscience integrates psychoanalysis within science. Each of the debaters will present fundamental implications for clinical work.
2 Contact Hours for the program in its entirety. 2 CME/CE credits offered. See details below.
BIOGRAPHIES
Ariane Bazan, Ph.D., who holds doctorates both in Biology and in Psychology, is a psychoanalyst in private practice. She is a professor of clinical psychology and psychopathology at the University of Lorraine (France) and the Université libre de Bruxelles (Belgium). Dr. Bazan has also been conducting research for some fifteen years that has resulted in 120 publications, including one book, Des fantômes dans la voix: Une hypothèse neuropsychanalytique sur la structure de l’inconscient (Editions Liber), and twenty-one book chapters. She is a founding member of the International Neuropsychoanalysis Association (NPSA) and was its liaison officer for Europe from 2014 to 2019. A former chief editor of the Psychoanalysis and Neuropsychoanalysis section of Frontiers in Psychology, Dr. Bazan is a monthly columnist for the Belgian newspaper De Standaard discussing general societal and political matters and contributing to the life of ‘psychoanalysis in the city’. She has been a member of the Superior Health Council in Belgium and, at the invitation of the Belgian Administration, she helped manage the Covid crisis from September to December 2020 (before moving to France in 2021). At the Université de Lorraine, she is Director of the Interpsy laboratory and a co-coordinator of a French academic network on neuropsychoanalysis, Réseau Francophone Psychanalyse et Neuroscience (RFPN). Considering psychoanalysis a science, Dr. Bazan is currently engaged in organizing and instantiating a productive international dialogue between psychoanalysis and adjacent scientific disciplines, such as cognitive neuroscience and psycho- and neurolinguistics as well as in developing a properly experimental section of psychoanalysis.
Professor Mark Solms holds the Chair of Neuropsychology at the Neuroscience Institute of the University of Cape Town and Groote Schuur Hospital. He has received numerous prizes and honours, such as the Sigourney Prize, the IPA’s Outstanding Scientific Achievement Award, and Honorary Fellowship of the American College of Psychiatrists. He is Training Director of the South African Psychoanalytical Association, Director of the Science Dept. of the American Psychoanalytic Association, and was until recently Research Chair of the International Psychoanalytical Association. Professor Solms has published 350 articles in both neuroscientific and psychoanalytic journals, and he has authored eight books. The Brain and the Inner World was translated into 13 languages. His collected papers were published recently as The Feeling Brain. His latest book, The Hidden Spring, appeared in early 2021. He is the editor and translator of the forthcoming Revised Standard Edition of the Complete Psychological Works of Sigmund Freud (24 vols) and Complete Neuroscientific Works of Sigmund Freud (4 vols).
Educational Objectives: Upon completion of this activity, participants should be able to:
- Describe evidence presented by the debaters as to whether or not neuroscience and psychoanalysis are a single science.
- Summarize several clinical implications of each debater’s theoretical views.
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American Psychoanalytic Association and the New York Psychoanalytic Society & Institute. The American Psychoanalytic Association is accredited by the ACCME to provide continuing medical education for physicians.
The American Psychoanalytic Association designates this Live Activity for a maximum of [2] AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
IMPORTANT DISCLOSURE INFORMATION FOR ALL LEARNERS: None of the planners and presenters for this educational activity have relevant financial relationship(s)* to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. *Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.